Fed. Circ. Lifts Block On Generic Lovenox Sales

Law360, New York (January 26, 2012, 4:29 PM EST) -- The Federal Circuit has granted Watson Pharmaceuticals Inc. and Amphastar Pharmaceuticals Inc. a stay of a preliminary injunction won by Momenta Pharmaceuticals Inc. that prevented them from marketing or selling a generic equivalent to blood-thinning medication Lovenox, Watson said Thursday.

Amphastar and Watson plan to launch a competing enoxaparin sodium injection product immediately, according to a statement from Watson.

Cambridge, Mass.-based Momenta and partner Novartis AG are currently the only companies that market a generic version of Sanofi SA's Lovenox in the U.S.

On Tuesday, attorneys...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.